Purpose

Evaluate the efficacy of weekly adalimumab (ADA) in patients with non-infectious ocular inflammation who failed standard every other week (EOW) dosing.

Design

Single-center, retrospective, study.

Subjects

Patients with uncontrolled inflammation on ADA EOW who were escalated to weekly dosing.

Methods

Chart review conducted at Northwestern University, January 2012 to April 2019.

Outcome: Number of treatment successes on weekly ADA at 6 and 12 months.

Results

Fourteen of 25 patients (56%) achieved disease control at 6 months; no additional failures occurred at 12 months.

Conclusion

Weekly ADA is a reasonable treatment option in patients with recalcitrant inflammation on standard dosing.

中文翻译：

---

每周使用阿达木单抗治疗难治性眼炎的成功率。

目的

评估每周一次阿达木单抗（ADA）在非感染性眼部炎症患者中每两周一次标准剂量（EOW）给药失败的疗效。

设计

单中心回顾性研究。

科目

ADA EOW上炎症未得到控制的患者，已升级为每周一次给药。

方法

2012年1月至2019年4月在西北大学进行的图表审查。

结果：在6和12个月每周一次ADA的治疗成功次数。

结果

25名患者中有14名（56％）在6个月时达到了疾病控制；在12个月内没有发生其他故障。

结论

对于标准剂量的顽固性炎症患者，每周ADA是合理的治疗选择。